{"id":75577,"title":"Omega Diagnostics Gp (ODX.L) Notice of Trading Update and Investor Presentation","publisher":"Share Talk","author":"sharetalk","published":"2020-10-20T09:32:38+00:00","modified":"2020-10-20T09:32:38+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-notice-of-trading-update-and-investor-presentation/","markdown_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-notice-of-trading-update-and-investor-presentation.md","json_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-notice-of-trading-update-and-investor-presentation.json","category":"Healthcare","categories":["Healthcare"],"tags":["Abingdon Health","Colin King","COVID-19","Medical","ODX","Omega Diagnostics Gp","scientists","UK Government","UK-RTC","University of Oxford"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Omega (AIM: ODX),** the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it will release a trading update for the six months ended 30 September 2020 on Wednesday 28 October 2020.\n\nOn the same day **Colin King, CEO, and Kieron Harbinson, CFO,** will provide a live investor presentation via the Investor Meet Company (IMC) platform at 4.30pm.\n\nThe presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics plc via the following link:\n\n[https://investormeetcompany.com/omega-diagnostics-group-plc/register-investor .](https://investormeetcompany.com/omega-diagnostics-group-plc/register-investor%20.)\n\nFor those investors who have already registered and added to meet the Company, they will automatically be invited.\n\nQuestions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the “Ask a Question” function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards."}